Abstract:Background: Patients with metastatic nasopharyngeal cancer (NPC) who experienced disease progression after standard therapy have limited treatment options. NPC is closely associated with Epstein–Barr Virus (EBV) infection and has been reported to have high levels of PD-L1 expression and tumor infiltrating lymphocytes, favoring immune-therapy potential in treating NPC. JS001, a humanized recombinant IgG4 antibody against PD-1, selectively blocks the interactions of PD-1 with its ligands PD-L1 and PD-L2, and promotes antigen specific T cell activation. Phase I studies of JS001 in subjects with heavily pretreated solid tumors had demonstrated an acceptable safety profile in doses up to 10 mg/kg Q2W. Methods: Refractory/metastatic NPC Patients received JS001 3 mg/kg Q2W until disease progression or unacceptable toxicity. All patients with measurable disease were assessed for clinical response every 8 weeks. Tumor PD-L1 expression (SP142) and plasma EBV DNA levelwere monitored for correlation with clinical response. Results: Between Dec 22th 2016 and May 4th 2018, 139 NPC pts were enrolled into the study. The median age was 46 years, 84% male (n = 117), with average 3.4 lines of prior systemic therapies. By Nov 15th 2017, treatment related AEs occurred in 84% patients, which were mostly grade 1 or 2, including fever (18.2%), hypothyroidism (18.2%), proteinuria (10.9%), fatigue (9.1%), TBIL increase (9.1%), leukopenia (9.1%) and anemia (7.3%). Grade ≥ 3 treatment related AEs occurred in 14.5% patients. Out of 52 evaluable pts by Jan 2018, 16 partial responses (30.8% ORR) and 16 stable diseases (61.5% DCR) were observed. PD-L1+ pts had slightly higher ORR 38.5% and 65.4% DCR. Interestingly, an average drop of 47-fold plasma EBV DNA copy number was observed in responding pts, which typically proceeded the radiographic identification of clinical benefits. Conclusions: PD-1 mAb JS001 has demonstrated encouraging clinical activity in heavily pretreated NPC pts and a manageable safety profile. A change in plasma EBV DNA copy number might serve as a prognosis marker for NPC upon immunotherapy. Clinical trial identification: NCT02915432. Legal entity responsible for the study: Shanghai Junshi Biosciences Co. Funding: Shanghai Junshi Biosciences Co. Disclosure: H. Wu, H. Feng, S. Yao: Employee: Shanghai Junshi Biosciences Co. All other authors have declared no conflicts of interest.

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer

Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China

Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC

Recombinant Humanized Anti-Pd-1 Monoclonal Antibody (JS001) in Patients with Refractory/metastatic Nasopharyngeal Carcinoma: Preliminary Results of an Open-Label Phase II Clinical Study

Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer

Preliminary Results With Tislelizumab, An Investigational Anti-Pd-1 Antibody, In Chinese Patients With Nasopharyngeal Cancer (Npc).

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma

Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer

Randomized Clinical Trial of Pembrolizumab Vs Chemotherapy for Previously Untreated Chinese Patients with PD‐L1‐positive Locally Advanced or Metastatic Non–small‐cell Lung Cancer: KEYNOTE‐042 China Study

Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis

The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal carcinoma patients

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma

Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer

Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study

909P A Phase II Study of the Anti-Programmed Cell Death-1 (PD-1) Antibody Penpulimab in Patients with Metastatic Nasopharyngeal Carcinoma (NPC) Who Had Progressed after Two or More Lines of Chemotherapy: Updated Results

Chemoradiotherapy plus immunotherapy for locoregionally advanced nasopharyngeal carcinoma: A cost-effectiveness analysis

Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma